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A thromboxane synthetase antagonist ameliorates progressive
renal disease of Dahl-S rats
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A thromboxane synthetase antagonist ameliorates progressive renal
disease of Dahl.S rats. Recent studies have suggested a role for
thromboxane in the progression of renal disease. The current study
evaluated the role of this arachidonic acid metabolite in a model of renal
disease which bears many biologic similarities to that in the kidneys of
patients with chronic progressive renal failure. The model is that
induced by ferritin-anti-ferritin immune complex nephritis in Dahl-salt
sensitive rats rendered hypertensive by a high salt intake. Rats with this
model of renal disease were chronically given a thromboxane synthe-
tase antagonist OKY-046 or a placebo treatment from 16 to 29 weeks of
age. Sequential observations of serum creatinine and 24-hour urinary
protein excretion showed an ameliorating effect of OKY-046 on these
renal parameters. Histologic examination of the kidneys also showed
significantly less glomerular sclerosis in OKY-046 treated animals. The
efficacy of OKY-046 was monitored by measurements of serum TXB2
levels and of glomerular production of TXB2 (and other prostaglandins);
amounts of TXB2 were significantly reduced in the OKY-046 group. It
is concluded that blockade of thromboxane generation has been suc-
cessful in ameliorating the functional and structural lesions in this
model of renal disease, providing further support to the thesis that
thromboxane is an important mediator in events leading to eventual
chronic renal failure and sclerosis.
In human renal disease and in several models of experimental
renal disease, recent studies have implicated a role for throm-
boxane in the genesis of renal functional deterioration and
proteinuria [1—7]. We elected to study the role of this mediator
in a model of renal disease with many features analogous to
human renal disease. The model is produced by inducing
chronic ferritin-anti-ferritin immune complex nephritis in Dahl
salt-sensitive (S) rats which are rendered hypertensive by a high
salt intake [8]. Histologically, the kidneys of these animals
show mesangial expansion and glomerular sclerosis. The role of
thromboxane as a mediator of renal injury was assessed with
use of a thromboxane synthetase antagonist, OKY-046.
Methods
Materials
Rat chow containing 2 1.0% protein and either 0.3% NaC1 or
8.0% NaC1 was purchased from Teklad (Madison, Wisconsin,
USA). Cadmium-free equine spleen ferritin was purchased from
Calbiochem Behring Company (La Jolla, California, USA) and
bovine serum albumin from Sigma Chemical Company (St.
Louis, Missouri, USA). Earle's balanced salt solution and n-2-
hydroxyethylpiperazine-n' 2 ethanesulfonic acid (HEPES) from
Gibco (Grand Island, New York, USA). Thromboxane B2
TXB2[3H], 6-keto-PGF1a [3H] RIA kit, and PGE2 [1251] RIA kits
were purchased from New England Nuclear (Boston, Massa-
chusetts, USA). OKY-046, (E)-3-[4-(l-imidazolylmethyl) phe-
nyl]-2-propenoic acid hydrochloride monohydrate, a thrombox-
ane synthetase inhibitor [9], was from Ono Pharmaceutical
Company (Osaka, Japan).
Experimental design
This is summarized in Figure 1. Five-week-old male Dahl rats
(Brookhaven National Laboratories, Brookhaven, New York,
USA) were housed in individual cages with free access to water
and standard rat chow containing 0.3% NaCI until 15 weeks of
age. Forty-eight rats were immunized by intraperitoneal injec-
tions of equine spleen feritin at a dose of 4 mgIlOO g body
weight, five days a week from 8 to 15 weeks of age. Thereafter,
they were divided into two groups. Rats in the placebo group,
composed of 24 immunized rats, were fed approximately 30 mg
of 8.0% NaC1 chow daily and given 1.5 ml of distilled water per
gavage twice a day from 16 weeks to 29 weeks of age. Rats in
the OKY-046 treated group, composed of 24 immunized rats,
were pair fed 8.0% NaCl chow against the placebo group, and
were treated with OKY-046 (thromboxane synthetase inhibitor)
at a concentration of 20 mg/kg body weight in 1.5 ml distilled
water per gavage twice a day from 16 weeks to 29 weeks of age.
The dose of OKY-046 was established in studies on a
separate group of 9 OKY-046-treated and 9 placebo-treated
rats. They were studied on an identical protocol, except that the
experiment was terminated at 19 weeks of age when the serum
creatinine levels were in the normal range, and when blood
pressure and urine protein excretion were similar in the OKY-
046 and placebo treated groups. Glomerular thromboxane pro-
duction was reduced by 39% in the OKY-046 group compared
to the placebo group.
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Body weights were obtained weekly, and systolic blood
pressure was measured without anesthesia by the tail cuff
method every two weeks. The average of five successive
readings for each animal was obtained.
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Fig. 1. Experimental design.
Sample preparation
Samples of urine were collected using metabolic cages over a
24-hour period, and their protein content was determined by the
binding of Coomassie brilliant blue [10]. Blood for serum
creatinine studies was collected via the tail vein. Serum creat-
mine was measured kinetically [11]. Blood for measuring plate-
let thromboxane B2 generation was collected via the tail vein at
the end of study, incubated at 37°C for 30 minutes and centri-
fuged at 5000 rpm for 10 minutes. The prepared sera were
stored at —70°C until assayed.
Renal tissue processing
Renal tissue specimens were obtained from all rats at 15
weeks and at sacrifice or death. The animals were anesthetized
with a peritoneal injection of 30 mg/kg of ketamine hydrochlo-
ride and 3 mg/kg of xylazine. At 15 weeks, the left kidney was
exposed through a flank incision in anesthetized animals, and
cortical tissue samples were obtained by renal biopsy using a
scalpel blade. At 29 weeks, both kidneys were perfused by 50
ml of Earle's balanced salt solution (EBSS) and placed in ice
cold EBSS immediately after left renal tissue was obtained. For
light microscopy, tissues were fixed in Mossman's fixative (40%
formaldehyde, 48% alcohol, 2% glacial acetic acid) and embed-
ded in paraffin.
Sections, 2 to 3 p. thick, were stained with periodic acid Schiff
(PAS), Masson's trichrome, and Lendrum stains. All sections
were coded and assessed in a blind fashion. By light micros-
copy, glomerular mesangial expansion was analyzed semiquan-
titatively on a scale ranging 0 to 3+. The number of glomeruli in
each specimen showing global sclerosis and the number show-
ing segmental sclerosis were enumerated separately. In addi-
tion, segmental sclerosis was divided into two main compo-
nents, segmental collapse and segmental hyalinosis. We defined
segmental hyalinosis as segmental folding of the glomerular
basement membrane with entrapment of amorphous material or
segmental disappearance of cellular elements from the tuft. The
glomerular sclerosis score was calculated from the formula
[percent of globally sclerosed giomeruli + 1/2 (percent of
segmentally scierosed glomeruli)].
Glomerular isolation
At 29 weeks, animals were anesthetized with ketamine hy-
drochloride and xylazine, and a cannula was inserted into the
lower aorta. Subsequently, the aorta was clamped above the
right renal artery, the renal veins were cut, and blood was
rinsed from the kidney by perfusion with 50 ml EBSS. When the
renal effluent was clear, the kidneys were removed ind placed
in ice cold EBSS immediately. After obtaining renal tissue for
histologic study, the renal capsules were removed and the
cortex was separated from the medulla. The cortical tissues
were minced into 1 to 2 mm fragments and passed by a spatula
through a stainless steel screen of a 180 p. sieve. They were
rinsed with EBSS through successive screens of a 140 p. sieve.
The sieved tissue, suspended in EBSS was passed through a 25
gauge needle. Glomeruli were trapped on a 74 p. sieve. To
29 obtain high purity, the glomerular suspension was passed
through a 140 p. sieve again, and rinsed with EBSS on a 74 p.
sieve. Purity of the isolated giomeruli was determined micro-
scopically by counting the number of glomerular and non-
glomerular particles suspended in a given volume. The final
glomerular suspensions contained more than 95% decapsulated
glomeruli. All preparative steps were performed at 4°C,
Incubations
Isolated glomeruli were suspended in modified EBSS, PH
7.4, containing BSA 1 mg/mi, 25 mrs HEPES. Glomeruli were
then incubated in a volume of 1.0 ml media at 37°C for 60
minutes in a Dubnoff shaking water bath (100 cycles/mm). At
the end of the incubation, the glomeruli were centrifuged at
10,000 rpm for 30 minutes, the supernatants were collected and
frozen at —70°C until radioimmunoassay for eicosanoids. Gb-
merular protein concentration was determined according to the
method of Lowry et a! [121 with BSA as a standard.
Radioi,nmunoassay
Glomerular supernatants without prior extraction were as-
sayed for TXB2, 6-keto-PGF1,,, and PGE2. Serum samples were
assayed for TXB2 [13]. Both samples were diluted in 50 mM
phosphate buffer (PH 7.3) containing 0.1% gelatin at a dilution
of 1: 10 to 1:500. A blank value obtained with the medium
incubated in the absence of glomeruli was subtracted. Assays
for PG and TXB2 were done according to the New England
Nuclear RIA Kit instruction manual. The sensitivities of the
assays for TXB2, 6-keto-PGF1, and PGE2 were respectively
50, 100 and 5 pg/mi. For TXB, the coefficient of variation for
multiple measurements on a single sample on one day was
2.7%, for samples on separate days 5,5%. For glomerular
preparations, results were expressed as nanograms of TXB2, 6-
keto-PGF1a, and PGE2 per mg of protein per hour.
Statistical Analysis
The Wilk Shapiro test was used to assess the normality of
distribution of data. Serum creatinine, urinary protein excretion
rate, serum TXB2, and glomerular production of PG and TXB2
were not normally distributed. The data were logarithmically
transformed and the log transformed data were normally dis-
tributed. Results were analyzed by Student's i-test and the
Wilcoxon non-paired rank sum test. For values distributed
normally without transformation, results were expressed as
arithmetic means and standard errors of the means. For log
normally distributed values, results were expressed as geomet-
ric means with the standard errors of the means. Correlations
were performed by linear regression analysis.
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Survival, body weight and systolic blood pressure
Eight rats in the placebo group, and three in the OKY-046
group died prior to sacrifice; the presumptive cause of death
was severe hypertension. The results of the body weight and
blood pressure determinations are shown in Figure 2. Body
weight increased progressively until week 15; thereafter, there
was only a slight further increase. Systolic blood pressures rose
throughout the course of study in both groups of rats. The mean
systolic blood pressure of the two groups of animals did not
differ.
Twenty-four-hour urinary protein excretion
The 24-hour urinary protein excretion of both groups of rats
showed a parallel increase with time until week 15 (Fig. 3).
Thereafter, rats in the placebo group exhibited more marked
proteinuria at subsequent time periods. By the 28th week, the
mean 24-hour urinary protein excretion in the placebo group
was 231 mg/24 hours, and that in the OKY-046 group was 134
mg/24 hours (P < 0.00 1).
Serum creatinine
Renal function, assessed by serum creatinine measurements,
was similar in both groups of rats until week 23 (Fig. 3).
Thereafter the placebo group, as compared to the OKY-046
group, showed more marked increases in serum creatinine with
time. At sacrifice, the mean serum creatinine was 0.75 mgIlOO
ml in the placebo group compared to 0.57 mg/lOO ml in the
OKY-046 group (P < 0.0001). As some rats died in each group
prior to sacrifice, a survival curve was constructed (Fig. 4) to
show the proportion of rats at each time period surviving with
approximately one-half normal renal function (serum creatinine
<0.7 mg/dl). The difference between the two groups of rats was
even more strikingly shown.
Histologic analysis
Table 1 shows selected histologic findings in renal tissue at
week 15 and at the time of sacrifice or death. At week 15,
glomeruli of both groups of animals showed a mild increase of
mesangial matrix and segmental sclerosis in a small number of
glomeruli. At sacrifice or death, mesangial expansion and
glomerular sclerosis were increased in both groups of animals.
Detailed analysis showed that, whereas segmental collapse was
equivalent in the kidneys of both groups of animals, segmental
hyalinosis and global sclerosis were significantly more pro-
nounced in the placebo group. Thus, the mean percent of
glomeruli showing segmental hyalinosis was 10.4% in the pla-
cebo group and 7% in the OKY-046 group. Mean percent of
glomeruli showing global sclerosis was 7.3% in the placebo
group compared to 1.2% in the OKY-046 group. Total sclerosis
score was 18.3% in the placebo group compared to 8.3% in the
OKY-046 group. Figure 5 shows the distribution of the glomer-
ular sclerosis score among the rats of the two groups. It is
apparent that the higher degrees of sclerosis observed were
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Fig. 2. Body weight and systolic blood pressure of rats during the
course of the study. (Symbols are: (0) placebo; (S) OKY = 046.)
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Fig. 3. Serum creatifline and 24-hour urinary protein excretion of the
two groups of rats during the course of the study. Values represent
means SE of the observations. Differences between the geometric
means of serum creatinine of the two groups of rats were statistically
significant after the 23rd week (P < 0.001). Differences between the
geometric means of the 24 hour urinary protein excretion of the two
groups were statistically significant after the 24th week (P < 0.008).
Symbols are: (0) placebo; (•) OKY-046.
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23±2 81±9 27±1 68±5Number of glomeruli/
rat
Mesangial expansion
Grade of expansion 0.1 0.04 1.2 0.06 0.1 0.02 1.1 0.06
Glomerular sclerosis
Segmental sclerosis 0.4 0.2 7.6 0.9 2.0 0.8 7.1 0.8
% collapse
% hyalinosis
Global sclerosis
% sclerosis
Sclerosis score 0.5 0.2 18.3 2.5 1.3 0.6 8.3 0.8"
a P < 0.03
"P c o.ooi
' P < 0.0001
found only in the kidneys of the placebo group. The proportion
of animals at each time period surviving with a sclerosis score
<12 is shown in Figure 4 (inset). Representative examples of
the histology in the two groups are shown in Figure 6.
Prostaglandin production by isolated glomeruli
Figure 7 shows the amounts of TXB2, 6-keto-PGF1a and
PGE2 produced by isolated glomeruli. The mean concentration
of TXB2 produced by isolated glomeruli of the rats in the
placebo group was significantly higher than that produced by
the glomeruli of rats in the OKY-046 group, being 4.98 ng/mg
0 6 12 18 24 30 36 42
Glomerular sclerosis score
Fig. 5. Distribution of glomerular sclerosis among the rats in the two
groups. Note that rats in the placebo group (A) only exhibited higher
degrees of glomerular sclerosis (sclerosis score >18). (B) OKY-046
group.
protein/hr and 2.08 ng/mg protein/hr, respectively (P < 0.0003).
By contrast, the mean concentrations of 6-keto-PGF1a and
PGE2 produced by the isolated glomeruli of the two groups of
rats were not significantly different. Thus, the mean concentra-
tions of glomerular 6-keto-PGF1, produced for the placebo
group and for the OKY-046 group were 3.66 ng/mg protein/hr
and 2.52 ng/mg protein/hr, respectively. The mean concentra-
tions of glomerular PGE2 produced for the placebo group and
for the OKY-046 group were 3.41 Pg/mg protein/hr and 2.62
ng/mg protein/hr, respectively.
Serum TXB2 levels
The serum concentration of TXB2 of the two groups of rats
are displayed in Figure 8 The mean serum TXB2 concentration
of the placebo group (158.8 ng/ml) was significantly higher than
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FIg. 4. The proportion of rats surviving at each time point with a serum
creatinine level <0.7 mg/dl. The inset shows the proportion of rats at
each time point with a glomerular sclerosis score <12. Symbols are: (0)
placebo; (S) OKY-046.
Table 1. Histologic analysis
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Fig. 6. Light micrographs of representative
glomeruli from rats in the placebo (A) and
OKY-046 treated (B) groups. (A and B, PAS
stain x850). (A) Global or segmental sclerosis
with hyalinosis (arrows) are present in three
glomeruli. An additional glomerulus shows
collapse with segmental sclerosis (asterisk).
(B) One glomerulus contains a small collapsed
sclerotic segment (arrowhead).
the level obtained for the rats of the OKY-046 group (73.1
ng/ml, P < 0.001).
Relationship of glomerular eicosanoid production to urinary
protein excretion, renal function and histology
Glomerular eicosanoid production was measured only at
sacrifice; the values may be presumed to reflect eicosanoid
production prior to this time. When the data from all animals
were examined, there was a significant positive relationship
between both log urine protein excretion at 28 weeks and
glomerular sclerosis at sacrifice, and log glomerular TXB2
production (r = 0.76: P < 0.001 and r = 0.71: P < 0.001,
respectively); this relationship was equal in both the placebo
and OKY-046 treated groups.
There was a positive relationship between glomerular pro-
duction of each eicosanoid and serum creatinine at sacrifice, a
Table 2. Relationship between log serum creatinine and log
glomerular eicosanoid production
Log creatinine
with b r P
Log PGE2 +0.098
(0.033, 0.163)
0.461 0.004
Log 6-keto-PGF1a +0.095
(0.035, 0.156)
0.475 0.003
Log TXB2 +0.157
(0.112, 0.202)
0.768 <0.000001
a b is slope and (95% confidence limits of slope)
relationship most significant for TXB2 (Table 2). The slope of
the line defining the relationship was significantly steeper for
TXB2 than for PGE2 or PGI2; the predictive relationship (r2)
was also much stronger for TXB2 (0.59) than for PGE2 (0.21)
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Fig. 7. Eicosanoid production by isolated glomeruli of the two groups
of rats. Glomeruli were isolated by the technique described in methods
weeks and incubated in Earle's balanced salt solution for 60 minutes.
Supernatants were collected and the amount of eicosanoid produced
measured by radioimmunoassay. Bars and shaded areas represent the
means SE ng/mg/hour observations. The mean concentrations of
TXB2, per mg/protein, produced by isolated glomeruli were signifi-
cantly different for the two groups of rats (P < 0.0003); the mean
concentrations of 6-keto-PGF1, and PGE2 produced by isolated glomer-
uli were not significantly different between the groups of animals.
and PG!2 (0.23). Thus there was a stronger relationship between
serum creatinine and the amount of TXB2 than the amounts of
PGE2 or PG!2 produced.
Discussion
The results of the current study clearly show that adminis-
tration of the thromboxane synthetase antagonist, OKY-046
produced a beneficial effect in this model of renal disease
despite the persistance of high blood pressure. The beneficial
effect could be seen in kidneys of animals in the following
parameters: (a) reduction in the amount of proteinuria; (b)
slowing of renal functional deterioration as assessed by serum
creatinine measurements; and (c) reduction in the amount of
histologic scarring of the kidney as evaluated from the amount
of sclerosis. The efficacy of the agent OKY-046 in inhibiting
TXB2 generation was confirmed by measurement of serum
TXB2 levels and of the quantity of TXB2 produced by isolated
glomerular specimens. That the action of OKY-046 was selec-
tive to the generation of TXB2 was demonstrated by concurrent
measurements of the amounts of PGE2 and 6-keto-PGF1a pro-
duced by glomerular isolates, when no differences were ob-
served between values obtained for the OKY-046 treated group
and for the placebo group.
The mechanism by which the thromboxane synthetase antag-
onist OKY-046 exerts its beneficial effect in this model of renal
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disease is uncertain. Some clues are offered by previous stud-
ies. In an investigation on the role of thromboxane in nephro-
toxic serum nephritis, Lianos, Andres and Dunn [3] were able
to show a significant enhancement of glomerular TXB2 synthe-
sis as early as two to three hours after a single injection of rabbit
anti-rat GBM serum which persisted up until day 14 of the
illness. Furthermore, the study showed a correlation between
presacrifice 24-hour urine protein excretion and glomerular
TXB2 synthetic rates. Further investigations were done mea-
suring glomerular filtration rates and renal plasma flow in such
rats which were treated with either a thromboxane synthetase
inhibitor or a cyclooxygenase inhibitor. By these means, the
authors were able to demonstrate that disturbances in glomer-
ular thromboxane and prostaglandin production mediated the
changes in renal hemodynamics found in this model of renal
disease.
In another model of renal disease produced by subtotal
ablation of the rat kidney, chronic administration of OKY-1581,
an inhibitor of thromboxane synthetase could be shown to
ameliorate progression of the kidney disease as demonstrated
by improvements in glomerular ifitration rate, renal histology
and reduction of proteinuria as compared to control animals [4].
Based on studies of the effect of OKY-1581 on platelet aggrega-
tion, the authors proposed that OKY-1581 exerted its beneficial
effect by preventing platelet aggregation [14] and intraglomeru-
lar thrombosis which is a known precursor of renal sclerosis
[15]. Platelet aggregation could also lead to release of platelet
products which could influence permeability of glomerular
capillaries, thus accounting for the effect of OKY-1581 on the
proteinuria of this model.
Kelley, Sneve and Musinski [SI showed a correlation be-
tween intrarenal TXB2 synthesis and renal pathologic change in
PGE2
20.0
10.0
5.0
2.5
1.0
0.5
a)
E0
DCV
a)
Cu0
a)
0
C0
0
V0
0.00C
0
C.)
w
TxB2
0
0
'I
o Co
.0 -
a)a! >-0
6-Keto-PGF1
..
000
o •
$
o co
.0
a)
C.)
.!! >-
200
• 100
a)
C-
S
S
0,
50
0
o Co
.0
a)
C.)
.!! >-0 0
2
Fig. 8. Serum concentrations of TXB2 of the two groups of rats. Bars
and shaded areas represent means SE of observations. The mean
concentrations of serum TXB2 of the two groups of animals were
significantly different (P < 0.005).
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MRL-lpr and NZBxNZW strains of mice with spontaneous
lupus nephritis. They also demonstrated that treatment with
PGE1 reduced intrarenal TXB2 synthesis and prevented devel-
opment of renal disease; by contrast, treatment with ibuprofen,
a cylooxygenase inhibitor, did not reduce intrarenal TXB2
synthesis and did not modify development of renal disease in
spite of a 90% inhibition of platelet TXB2 production. Their data
indicated that the intrarenal level of TXB2 was important in
relation to the severity of the nephritis.
Finally, Remuzzi et al [6] clearly demonstrated in a model of
adriamycin-induced nephrosis that the augmented TXA2 seen in
this model could be shown to correlate with the increased
protein excretion. The authors speculated that the increased TX
generation might be responsible for altering glomerular base-
ment membrane permeability to protein.
In summary, the studies cited above suggest that thrombox-
ane synthetase antagonists might exert their salutory effect on
various forms of renal disease by their effects on renal hemo-
dynamics and/or on platelet aggregation. This is reflected in
better preservation of renal architecture and function, and in a
reduction in the amount of protein leaking through the glomer-
ulus. The current study provides further confirmation for these
findings in an experimental model which bears many histologic
similarities to the disease found in patients with chronic pro-
gressive renal failure. It suggests that further studies will be
required to determine the exact mechanism by which a throm-
boxane synthetase antagonist achieves its effect in this model.
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